Make the profile of
Quanthealth yours.

Company description

QuantHealth is an AI-driven healthcare company founded in 2020 that transforms drug development through advanced clinical trial simulations. Its in-silico platform enables pharmaceutical and biotechnology companies to predict how any patient will respond to any therapy, allowing sponsors to accelerate and de-risk their development processes across all clinical phases. Trusted by many of the world's top 50 pharmaceutical companies, QuantHealth has successfully simulated over 600 clinical trials with 85% endpoint prediction accuracy, and has been deployed across more than 45 diseases including oncology, immunology, cardiometabolic diseases, and gastroenterology.

The platform is powered by an omni-channel, integrated data framework bridging biomedical, clinical, and epidemiological domains. This includes data representing 350 million lives, a biomedical knowledge graph covering over 100,000 drug and mechanism data points, and curated results from 180,000 trials. Each simulated patient carries more than 10,000 individual data points, enabling highly granular, diverse, and realistic virtual trial populations whose response profiles closely approximate actual likely outcomes.

Core Platform Capabilities

• Clinical Trial Simulation: Generates virtual trial results in a format identical to real clinical trial outputs, including Kaplan-Meier analyses and progression-free survival data, providing researchers with exhaustive reports that mirror the depth and precision of actual trial data.
• Protocol Optimization: Enables data-driven clinical study design by simulating protocol variations and predicting their impact on outcomes, enrollment, and market performance.
• Enrollment Prediction: Forecasts patient enrollment patterns to support operational planning and cost reduction.
• Market Forecasting: Integrates market considerations alongside clinical outcomes to support commercially informed development decisions.
• Large Real-World Drug Model (LRDM v1.0): The industry's first pharmaco-clinical foundation model, capable of processing data from more than 100 million patients and billions of therapeutic data points in a single simulation.

Use Cases by Function

• Clinical Development: Protocol optimization, indication selection, target product profile (TPP) definition, probability of technical success (PTS) estimation, market forecasting, and enrollment prediction.
• Business Development: Search and evaluation across many assets (many-to-few), comparative deep dives (few-to-one), asset diligence and valuation, and asset out-licensing and disposition support.
• Portfolio Management: Portfolio prioritization, analysis of inter-portfolio synergy and competition, and identification of portfolio gaps and opportunities.

Therapeutic Areas and Case Studies

• Acute Respiratory Disease: AI-based clinical and operational optimization enabling cost reductions and improved likelihood of success.
• MASH (Metabolic Dysfunction-Associated Steatohepatitis): Cutting-edge clinical trial design combining AI-driven clinical optimization with population PK-PD modeling.
• Head and Neck Cancer: AI-based clinical optimization of an antibody-drug conjugate in metastatic HNSCC to maximize clinical trial success.
• Inflammatory Bowel Disease: AI-based clinical prioritization of a portfolio of potential assets to maximize clinical trial success.

Recognition, Partnerships, and Key Milestones

• Recognized by CB Insights, Frost & Sullivan, Fast Company, and Inc. Best in Business, and supported by AstraZeneca, BARDA, the Israel Innovation Authority, and Plug and Play.
• Received a strategic investment from Sanofi Ventures to advance AI-powered digital twins and clinical trial simulations.
• Delivered $31.4 million in savings for a top-10 pharmaceutical company across more than 350 simulated trials.
• Achieved 8x financial growth across life sciences engagements and expanded its product portfolio and client footprint significantly.
• The platform is now deployed across 23 therapeutic areas.

Team and Expertise

• QuantHealth's multidisciplinary team spans data science, biology, medicine, bioinformatics, mathematics, software engineering, product management, immunology, pharmacology, and epidemiology.
• 36% of team members hold PhDs or MDs, and 75% possess advanced degrees.
• Leadership includes co-founders Orr Inbar (CEO) and Arnon Horev (Chief Strategy & Operations), alongside executives covering finance, commercial, and sales functions.
• The advisory board includes prominent figures from the pharmaceutical and academic communities.

QuantHealth's vision is to transform the future of healthcare by accelerating the development of groundbreaking therapies, bringing more and better treatments to patients worldwide faster and more affordably than ever before.

AI-generated · replace with your own

Software attributed to Quanthealth

• QuantHealth PlatformView
• Clinical Development ModuleView
• Business Development ModuleView
• Portfolio Management ModuleView

Edit all with premium access